Fig. 7: Macrophage YTHDC2 predicts the clinical efficacy of chemotherapy (with/without anti-PD-L1) in TNBC. | npj Precision Oncology

Fig. 7: Macrophage YTHDC2 predicts the clinical efficacy of chemotherapy (with/without anti-PD-L1) in TNBC.

From: YTHDC2 manipulates anti-tumoral macrophage polarization and predicts favorable outcomes in triple negative breast cancer

Fig. 7

a, d, g UMAP plots for macrophages from samples with different responses to chemotherapy with/without anti-PDL1 (a), chemotherapy (d), and chemotherapy + anti-PDL1 (g) derived from the combined plot in Fig. 2a (excluding monocyte cluster). Each dot represents an individual cell. Color coding is shown in Fig. 2a. b, e, h Comparison of averaged YTHDC2 expression levels between macrophages in samples receiving chemotherapy with/without anti-PDL1 (b), chemotherapy alone (e), or chemotherapy + anti-PDL1 (h) with different clinical responses, related to the UMAP plot in Fig. 2a. c, f, i Box plots showing expression level of YTHDC2 in tumor macrophages from patient samples receiving chemotherapy/chemotherapy + anti-PDL1 (c), chemotherapy alone (f), or chemotherapy + anti-PDL1 (i) with different clinical responses. Each dot represents an individual cell (median test, *P < 0.05).

Back to article page